Adaptive Biotechnologies (ADPT)
(Delayed Data from NSDQ)
$10.33 USD
+0.09 (0.88%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $10.45 +0.12 (1.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ADPT 10.33 +0.09(0.88%)
Will ADPT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADPT
Moderna (MRNA) Reports Q2 Loss, Beats Revenue Estimates
Are Medical Stocks Lagging Adaptive Biotechnologies (ADPT) This Year?
ADPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adaptive Biotechnologies (ADPT) Surges 12.5%: Is This an Indication of Further Gains?
What Makes Adaptive Biotechnologies (ADPT) a New Buy Stock
Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?
Other News for ADPT
COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake
Adaptive Biotechnologies price target raised by $2 at BTIG, here's why
BTIG Increases Price Target for Adaptive Biotechnologies (ADPT) to $13
Aristotle Large Cap Growth Q2 2025 Commentary
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics